- Home
- TOVX vs DRMA Comparison
TOVX vs DRMA Comparison
Compare TOVX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- DRMA
- Stock Information
- Founded
- TOVX 2001
- DRMA 2014
- Country
- TOVX United States
- DRMA United States
- Employees
- TOVX N/A
- DRMA N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- DRMA Health Care
- Exchange
- TOVX Nasdaq
- DRMA Nasdaq
- Market Cap
- TOVX 3.8M
- DRMA 3.3M
- IPO Year
- TOVX 2006
- DRMA 2021
- Fundamental
- Price
- TOVX $0.42
- DRMA $3.97
- Analyst Decision
- TOVX Hold
- DRMA Strong Buy
- Analyst Count
- TOVX 1
- DRMA 1
- Target Price
- TOVX N/A
- DRMA $10.00
- AVG Volume (30 Days)
- TOVX 13.2M
- DRMA 344.3K
- Earning Date
- TOVX 11-11-2025
- DRMA 11-12-2025
- Dividend Yield
- TOVX N/A
- DRMA N/A
- EPS Growth
- TOVX N/A
- DRMA N/A
- EPS
- TOVX N/A
- DRMA N/A
- Revenue
- TOVX N/A
- DRMA N/A
- Revenue This Year
- TOVX N/A
- DRMA N/A
- Revenue Next Year
- TOVX N/A
- DRMA N/A
- P/E Ratio
- TOVX N/A
- DRMA N/A
- Revenue Growth
- TOVX N/A
- DRMA N/A
- 52 Week Low
- TOVX $0.37
- DRMA $3.83
- 52 Week High
- TOVX $2.64
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- TOVX 48.00
- DRMA 38.17
- Support Level
- TOVX $0.39
- DRMA $3.83
- Resistance Level
- TOVX $0.86
- DRMA $4.44
- Average True Range (ATR)
- TOVX 0.08
- DRMA 0.41
- MACD
- TOVX 0.01
- DRMA -0.09
- Stochastic Oscillator
- TOVX 6.71
- DRMA 6.86
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.